Investment
Features
FeesSafety
Academy
More
Pluang+

Chainlink's CCIP token migration surpasses $7B in Q2 with 353% volume growth

Protocol Fundamentals
28 Sep 2026
Crypto Economy
View Source
Bullish
Chainlink's CCIP token migration surpasses $7B in Q2 with 353% volume growth

Chainlink's Cross-Chain Interoperability Protocol (CCIP) saw over $7 billion in token value migrated during Q2. The quarterly transaction volume reached $4.90 billion, marking a 353% increase compared to the same period last year. This surge highlights growing adoption and activity on Chainlink's interoperability platform, signaling strong momentum for cross-chain decentralized applications. Continued growth could enhance Chainlink's position in the blockchain ecosystem.

Chainlink's CCIP 2.0 launch and its reported $7 billion token migration and $4.90 billion quarterly transaction volume provide context for the broader crypto market. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Sep 29, 2026 00:41 WIB: out of 50 priced assets, 11 rose and 38 fell today. Notably, SXP dropped sharply by 46.27% to Rp37 with a typical hold time of 94 days, while ALGO and BAL gained 16.52% and 11.14%, priced at Rp2,441 and Rp16,297 respectively, with ALGO showing balanced buy/sell order activity and a longer hold time of 129 days.

More News

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

RGA stock set for 16.7% rise on strong earnings and favorable market conditions

Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...

Analyst Insights
Bullish
1 hour ago
Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

Mirum Pharmaceuticals' price target raised to $195 after key drug approvals and trial success

H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...

Analyst Insights
Bullish
1 hour ago
Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences stock jumps 176% after positive Phase 3 trial for retinal disease drug

Kodiak Sciences reported successful Phase 3 trial results for its retinal disease treatments Zenkuda and tabirafusp-ted, showing vision improvements comparable to Regeneron's Eylea. Zenkuda allowed 54% of patients to maintain a six-month dosing inter...

Market News
Bullish
2 hours ago
Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup keeps Neutral on Regeneron amid rising competition from Kodiak Sciences' eye drug success

Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals due to increasing competition in the ophthalmology sector. Kodiak Sciences reported positive Phase 3 trial results for its eye drugs, challenging Regeneron's key product, Eylea, e...

Analyst Insights
Neutral
3 hours ago
Bittensor proposes Gamma tokens to enable subnet collaboration via emission-backed credits

Bittensor proposes Gamma tokens to enable subnet collaboration via emission-backed credits

Bittensor has introduced a proposal for Gamma tokens, a new economic layer allowing its subnets to trade compute and inference services using credits backed by their own TAO emissions. This shifts TAO from being solely a reward token to also serving ...

Protocol Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App